Eytan Abraham

Vice President & Business Head, Cell Therapy, Gene Therapy • Nucleic Acids

Dr. Eytan Abraham heads the Resilience Cell, Gene, and Nucleic Acids Franchise Businesses, with a focus on partnering with leading Pharma, Biotech, and Clinical Centers to deliver best in class process development as well as clinical and commercial biomanufacturing. 

Prior to Resilience, Eytan established and led the Lonza heading Personalized Medicine Business Unit, as well as was head of Lonza’s Cell and Gene Therapy R&D.

Dr. Abraham has over 15 years of experience in the Cell and Gene space focusing on R&D, CMC, and Commercial development. He is the author of over 20 publications and inventor on 12 therapeutic and biomanufacturing patents.

He holds a Ph.D. in developmental and molecular biology from the University of Maryland Biotechnology Institute, and a post-doctorate in cell therapy and tissue engineering from the Harvard-MIT Biomedical Engineering Center and Harvard Medical School

Also Speaking

Jörg Schneider

Director, Principal Consultant • BioPharma Excellence

John Rasko

Professor • University of Sydney

Peter Zandstra

Professor • University of British Columbia

Also Speaking


Post-Event Report

Download the post-event report for Advanced Therapies Week 2023.

Investor List

Take a look at some of the investors who attended Advanced Therapies Week 2023.